For its NCEs in Israel, Japan, China and New Zealand
Suven Life Sciences announced that it has secured the grant of two (2) product patents from Israel (199300,205231), one (1) product patent from Japan (5536781), one (1) product patent from China (CN10259564) and one (1) product patent from New Zealand (601284) corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2027, 2028, 2029 and 2030 respectively.The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and Schizophrenia.
Powered by Capital Market - Live News
